---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-025338"
form_type: "8-K"
ticker: "BIAF"
cik: "0001712762"
company_name: "bioAffinity Technologies, Inc."
filed_at: "2026-05-27T12:30:16+00:00"
generated_at: "2026-05-27T12:36:46.126135+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# bioAffinity Technologies announces Mexican patent allowance for CyPath Lung cancer detection method

## Summary
- Mexican patent allowance for flow-cytometry methods to detect lung cancer using CyPath Lung.
- Patent will protect use of defined antibodies and TCPP porphyrin to label sputum cells.
- CyPath Lung demonstrated 92% sensitivity, 87% specificity, 88% accuracy, 99% NPV in trial.
- IP portfolio now includes patents in US, EU, China, Japan, Australia, Canada, and Mexico.

## SEC filing metadata
- accession: 0001493152-26-025338
- form_type: 8-K
- ticker: BIAF
- cik: 0001712762
- company_name: bioAffinity Technologies, Inc.
- filed_at: 2026-05-27T12:30:16+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1712762/000149315226025338/0001493152-26-025338-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1712762/000149315226025338/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-025338
- JSON: https://secwatch.observer/filing/0001493152-26-025338.json
- Plain text: https://secwatch.observer/filing/0001493152-26-025338.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.